Ekso Bionics Holdings, Inc. Q4 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Quarterly Performance (Q4 2024 vs. Q4 2023)

  • Revenue was 5.1 million dollars, up 5 percent from 4.8 million dollars.
  • Gross profit was 2.7 million dollars with a 53 percent margin, up from 2.4 million dollars and a 49 percent margin. Improvements were driven by supply chain efficiencies and reduced service costs.
  • Operating expenses were 4.9 million dollars, improving 15 percent from 5.8 million dollars last year, due to lower headcount and discretionary spending.
  • Net loss was 3.4 million dollars, compared to 3.2 million dollars last year. Net loss per share improved to 0.14 dollars from 0.22 dollars.
  • Cash used in operations decreased to 1.4 million dollars from 1.6 million dollars.

Full Year 2024 Performance (vs. 2023)

  • Revenue was 17.9 million dollars, slightly below 2023’s 18.3 million dollars. Management attributes the decline to:
    • Large independent hospital systems being off‑cycle for procurement in 2024.
    • A difficult comparison to 2023, which included fulfillment of a roughly 2 million dollar VA backlog inherited from the Parker Hannifin acquisition.
  • Gross profit increased to 9.5 million dollars with a 53 percent margin, compared to 9.1 million dollars with a 50 percent margin last year.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings. And welcome to the Ekso Bionics Holdings, Inc. Fourth Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone else requires operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Steven Kilmer. Thank you. Steven Kilmer: Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics Holdings, Inc. released financial results for the quarter and year ended December 31, 2024. A copy of the press release is available on our website. I would like to point out that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts shall be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations, are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events t

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional